Education
About Us
Working with TipRanks
Follow Us
AxoGen (AXGN)
NASDAQ:AXGN
AXGN Stock Chart & Stats
$23.77
>-$0.01(>-0.01%)
At close: 4:00 PM EST
$23.77
>-$0.01(>-0.01%)
Day’s Range― - ―
52-Week Range$9.22 - $23.83
Previous CloseN/A
Volume66.42K
Average Volume (3M)927.61K
Market Cap
$1.10B
Enterprise Value$903.86M
Total Cash (Recent Filing)$23.90M
Total Debt (Recent Filing)$19.75M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 03, 2026EPS Estimate
0.06Last Dividend Ex-Date
Jan 27, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding46,122,288
10 Day Avg. Volume1,122,640
30 Day Avg. Volume927,609
Financial Highlights & Ratios
PEG Ratio1.33
Price to Book (P/B)7.02
Price to Sales (P/S)3.89
P/FCF Ratio66.31K
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue4.21
Enterprise Value/Gross Profit5.63
Enterprise Value/Ebitda69.35
Forecast
1Y Price Target
$26.75Price Target Upside12.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.27
Revenue Forecast (FY)$219.72M
Bulls Say, Bears Say
Bulls Say
Market ExclusivityAvance has been granted Regenerative Medicine Advance Therapy designation; BLA approval would grant a period of 12 years of market exclusivity in the U.S.
Regulatory MilestonesAXGN completed significant regulatory milestones related to the Avance Nerve Graft BLA, including a late-cycle meeting and inspections under the FDA’s Bioresearch Monitoring program.
Revenue GrowthAxogen reported 23.5% year-over-year revenue growth, exceeding projections and demonstrating strong financial performance.
Bears Say
Government ShutdownThe government shutdown poses risks of FDA delays due to funding issues and potential backlog.
Major Amendment ReviewThe information submitted in response to an FDA request was deemed a Major Amendment, allowing for additional time for review.
Regulatory UncertaintyThe delayed PDUFA date adds some additional uncertainty on the setup through year-end.
AxoGen News
AXGN FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was $9.21 and its highest was $23.83 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $1.10B.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Mar 03, 2026 which is in 117 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Oct 29, 2025. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.072 by $0.048.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $1 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.06.
How many shares outstanding does AxoGen have?
AxoGen has 46,122,288 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of $0.12 in its last earnings report, beating expectations of $0.072. Following the earnings report the stock price went up 23.064%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in AXGN
AxoGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.75 (12.54% Upside)
$26.75 (12.54% Upside)
Blogger Sentiment
Bullish
AXGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 30.4%
Last 30 Days ▼ 30.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.39%
12-Months-Change
Fundamentals
Return on Equity
-1.90%
Trailing 12-Months
Asset Growth
12.72%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc. is a biotechnology company focused on the development and commercialization of innovative surgical solutions for peripheral nerve repair. Operating primarily in the healthcare sector, AxoGen provides a range of products that facilitate nerve repair and regeneration, including allograft and synthetic nerve conduits. Their core products, such as Avance® Nerve Graft and AxoGuard® Nerve Connector, are designed to enhance recovery and functional outcomes for patients undergoing surgical procedures involving nerve damage.
AXGN Company Deck
AXGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and operational performance across all target markets, driven by increased adoption and positive gross margin trends. However, some challenges were noted in reaching high potential account goals and the extended timeline for BLA approval. Despite these challenges, the overall sentiment is positive, given the robust financial performance and strategic progress.View all AXGN earnings summariesAXGN Stock 12 Month Forecast
Average Price Target
$26.75
▲(12.54% Upside)
Technical Analysis
Ownership Overview
1.77% Insiders
18.08% Mutual Funds
3.65% Other Institutional Investors
63.37% Public Companies and
Individual Investors